

# Ulrich B Keller

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6455915/ulrich-b-keller-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120  
papers

4,542  
citations

36  
h-index

66  
g-index

129  
ext. papers

5,516  
ext. citations

8.1  
avg, IF

4.89  
L-index

#	Paper	IF	Citations
120	Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. <i>Nature</i> , <b>2013</b> , 501, 421-5	50.4	342
119	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology,the</i> , <b>2016</b> , 3, e217-27	14.6	288
118	Targeting of hematopoietic progenitor cells with MR contrast agents. <i>Radiology</i> , <b>2003</b> , 228, 760-7	20.5	179
117	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. <i>Blood</i> , <b>2010</b> , 116, 1498-505	2.2	174
116	BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E2721-30	11.5	163
115	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology,the</i> , <b>2017</b> , 4, e510-e523	14.6	157
114	Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. <i>Cancer Cell</i> , <b>2005</b> , 7, 433-44	24.3	157
113	In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , <b>2015</b> , 7, 477-87	12	144
112	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 248-51	8.9	137
111	Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. <i>Theranostics</i> , <b>2015</b> , 5, 618-30	12.1	135
110	c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 7256-70	4.8	115
109	Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. <i>Nature Medicine</i> , <b>2016</b> , 22, 735-43	50.5	110
108	Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7067-79	12.9	108
107	Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. <i>FASEB Journal</i> , <b>2005</b> , 19, 992-4	0.9	95
106	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology,the</i> , <b>2016</b> , 3, e388-97	14.6	93
105	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i> , <b>2017</b> , 31, 846-852	10.7	88
104	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , <b>2019</b> , 394, 2271-2281	40	85

103	Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 410-6	8.9	84
102	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , <b>2017</b> , 8, 707	17.4	82
101	Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 1560-9	4.8	79
100	Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. <i>EMBO Journal</i> , <b>2007</b> , 26, 2562-74	13	78
99	First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 741-6	8.9	77
98	Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4127-33	2.2	64
97	Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin lymphoma treated with BEACOPP alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. <i>Lancet Oncology</i> , <b>2017</b> , 18, 454-463	21.7	62
96	CXCR4-directed theranostics in oncology and inflammation. <i>Annals of Nuclear Medicine</i> , <b>2018</b> , 32, 503-511	11.5	61
95	Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. <i>Oncotarget</i> , <b>2011</b> , 2, 599-609	3.3	60
94	Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. <i>JMIR MHealth and UHealth</i> , <b>2017</b> , 5, e81	5.5	57
93	Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. <i>Blood</i> , <b>2014</b> , 124, 2081-90	2.2	54
92	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF- $\kappa$ B and JNK activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E7230-8	11.5	51
91	Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1172-1179	4.7	50
90	[Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. <i>Theranostics</i> , <b>2017</b> , 7, 2350-2362	12.1	49
89	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. <i>Theranostics</i> , <b>2018</b> , 8, 369-383	12.1	42
88	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. <i>Oncotarget</i> , <b>2011</b> , 2, 448-60	3.3	38
87	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. <i>Haematologica</i> , <b>2016</b> , 101, 932-40	6.6	37
86	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 851-62	12	37

85	Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. <i>Nature Medicine</i> , <b>2014</b> , 20, 1401-9	50.5	36
84	FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. <i>Cancer Research</i> , <b>2012</b> , 72, 5014-24	10.1	35
83	Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues. <i>Analytical Chemistry</i> , <b>2014</b> , 86, 10568-75	7.8	34
82	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. <i>Gut</i> , <b>2020</b> , 69, 1472-1482	19.2	34
81	[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 34-43	8.8	33
80	Clinical presentation and characteristics of lymphoma in the head and neck region. <i>Head &amp; Face Medicine</i> , <b>2019</b> , 15, 1	2.4	33
79	Nfkb 1 is dispensable for Myc-induced lymphomagenesis. <i>Oncogene</i> , <b>2005</b> , 24, 6231-40	9.2	32
78	Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. <i>Blood</i> , <b>2011</b> , 118, 2712-22	2.2	29
77	Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 410-420	4.5	28
76	Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 724-738	4.5	28
75	Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 2266-72	9.4	27
74	GP130 activation induces myeloma and collaborates with MYC. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 5263-74	15.9	27
73	PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. <i>Nature Communications</i> , <b>2019</b> , 10, 1415	17.4	25
72	Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. <i>HemaSphere</i> , <b>2018</b> , 2, e160	0.3	23
71	Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. <i>Molecular Cancer Research</i> , <b>2010</b> , 8, 353-62	6.6	22
70	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1765-1771	8.9	21
69	Myc suppression of Nfkb2 accelerates lymphomagenesis. <i>BMC Cancer</i> , <b>2010</b> , 10, 348	4.8	21
68	Direct Parametric Image Reconstruction in Reduced Parameter Space for Rapid Multi-Tracer PET Imaging. <i>IEEE Transactions on Medical Imaging</i> , <b>2015</b> , 34, 1498-1512	11.7	20

67	Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. <i>Oncotarget</i> , <b>2014</b> , 5, 4050-9	3.3	20
66	Response assessment with the CXCR4-directed positron emission tomography tracer [Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. <i>EJNMMI Research</i> , <b>2017</b> , 7, 51	3.6	19
65	Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. <i>Journal of Immunotherapy</i> , <b>2014</b> , 37, 374-81	5	19
64	The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics. <i>Cell Reports</i> , <b>2019</b> , 29, 480-494.e5	10.6	18
63	Id2 is dispensable for myc-induced lymphomagenesis. <i>Cancer Research</i> , <b>2004</b> , 64, 7296-301	10.1	18
62	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. <i>Molecular Cell</i> , <b>2021</b> , 81, 1170-1186.e10	17.6	18
61	Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1399-1405	8.9	17
60	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. <i>Blood</i> , <b>2017</b> , 129, 598-608	2.2	16
59	Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. <i>Cancer Cell</i> , <b>2019</b> , 36, 250-267.e9	24.3	16
58	Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival. <i>Oncotarget</i> , <b>2013</b> , 4, 899-910	3.3	15
57	PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. <i>EJNMMI Research</i> , <b>2018</b> , 8, 90	3.6	15
56	Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7574-7574	2.2	14
55	Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies. <i>PLoS ONE</i> , <b>2012</b> , 7, e37433	3.7	14
54	Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in -ITD AML with concurrent epigenetic mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 108738-108759	3.3	11
53	Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 789-98	4.4	11
52	Design, synthesis and biological activity of N-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2018</b> , 33, 74-84	5.6	11
51	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. <i>Oncotarget</i> , <b>2020</b> , 11, 3688-3697	3.3	10
50	A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , <b>2021</b> , 137, 2646-2656	2.2	10

49	Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 4, 70-9	2.2	9
48	Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. <i>Molecular Oncology</i> , <b>2020</b> , 14, 3048-3064	7.9	9
47	The SUMO pathway in pancreatic cancer: insights and inhibition. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 531-538	8.7	9
46	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. <i>Cancer Research</i> , <b>2019</b> , 79, 3125-3138	10.3	8
45	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 1123-7	4.4	7
44	Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression. <i>Molecular and Cellular Biology</i> , <b>2012</b> , 32, 2416-27	4.8	7
43	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies <b>2021</b> , 9,		7
42	REGGAE: a novel approach for the identification of key transcriptional regulators. <i>Bioinformatics</i> , <b>2018</b> , 34, 3503-3510	7.2	6
41	Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
40	Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. <i>Blood Advances</i> , <b>2021</b> , 5, 2707-2716	7.8	6
39	Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	5
38	Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3227-9	1.9	4
37	Towards quantitative imaging biomarkers of tumor dissemination: A multi-scale parametric modeling of multiple myeloma. <i>Medical Image Analysis</i> , <b>2019</b> , 57, 214-225	15.4	4
36	An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma. <i>BMC Hematology</i> , <b>2014</b> , 14, 2	2.5	4
35	SDF1-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLC $\beta$ and RhoA. <i>Haematologica</i> , <b>2019</b> , 104, e288-e292	6.6	3
34	Regulation of hematopoietic growth factor production by genetically modified human bone marrow stromal cells expressing interleukin-1beta antisense RNA. <i>Journal of Interferon and Cytokine Research</i> , <b>2001</b> , 21, 851-60	3.5	3
33	Rationale for MYC imaging and targeting in pancreatic cancer. <i>EJNMMI Research</i> , <b>2021</b> , 11, 104	3.6	3
32	Cancer clinical trials - Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC). <i>Clinical and Translational Radiation Oncology</i> , <b>2018</b> , 13, 44-49	4.6	3

31	Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.. <i>Nature Communications</i> , <b>2022</b> , 13, 1009	17.4	3
30	NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	3
29	Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	2
28	Oncologist@/haematologist@ view on the roles of pathologists for molecular targeted cancer therapy. <i>Journal of Cellular and Molecular Medicine</i> , <b>2010</b> , 14, 805-17	5.6	2
27	Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma. <i>Oncotarget</i> , <b>2017</b> , 8, 78917-78929	3.3	2
26	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.. <i>European Journal of Cancer</i> , <b>2021</b> , 162, 45-55	7.5	2
25	Assessment of coronary artery disease during hospitalization for cancer treatment. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 200-210	6.1	2
24	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. <i>Leukemia</i> , <b>2021</b> , 35, 2895-2905	10.7	2
23	Investigation of spleen CXCR4 expression by [Ga]Pentixafor PET in a cohort of 145 solid cancer patients. <i>EJNMMI Research</i> , <b>2021</b> , 11, 77	3.6	2
22	Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [ <sup>18</sup> F]Fluorothymidine-PET. <i>Advances in Molecular Imaging</i> , <b>2015</b> , 05, 17-28	0.3	1
21	Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. <i>HemaSphere</i> , <b>2020</b> , 4, e398	0.3	1
20	High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	1
19	Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
18	Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.. <i>Nature Communications</i> , <b>2022</b> , 13, 281	17.4	0
17	90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6years.. <i>Annals of Hematology</i> , <b>2022</b> , 101, 781	3	0
16	Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 772809	5.3	0
15	Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-9	1.9	0
14	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinium (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. <i>HemaSphere</i> , <b>2021</b> , 5, e636	0.3	0

- 13 Characterization of retroviral vector derived DNA-isoforms by PCR and sequencing. *Journal Fur Verbraucherschutz Und Lebensmittelsicherheit*, **2019**, 14, 157-165 2.3
- 12 Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma. *Therapeutic Advances in Hematology*, **2012**, 3, 81-8 5.7
- 11 MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia. *Blood*, **2020**, 136, 5-5 2.2
- 10 Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. *Leukemia and Lymphoma*, **2021**, 1-9 1.9
- 9 Myc Promotes Tumorigenesis by Suppressing Nfkb2.. *Blood*, **2006**, 108, 1422-1422 2.2
- 8 The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism. *Blood*, **2019**, 134, 314-314 2.2
- 7 In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment. *Oncotarget*, **2015**, 6, 21827-39 3.3
- 6 Loss of Therapy-Induced Senescence in Myc-Driven Lymphomas Compromises Treatment Outcome In Vivo.. *Blood*, **2009**, 114, 1686-1686 2.2
- 5 Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. *Journal of Clinical Oncology*, **2012**, 30, e19031-e19031 2.2
- 4 NIPA Deficiency Leads To Acceleration Of The Lymphoma Development In E $\mu$ Myc Mice. *Blood*, **2013**, 122, 3681-3681 2.2
- 3 Proteinkinase C-Inhibitors Mitigate Microenvironment-Mediated Survival Of CLL Cells and Sensitise Malignant B Cells To Cytotoxic Drugs. *Blood*, **2013**, 122, 669-669 2.2
- 2 Non-Hodgkin Lymphoma Secondary to Hodgkin Lymphoma in an Adult Patient With Nijmegen Breakage Syndrome. *HemaSphere*, **2018**, 2, e140 0.3
- 1 A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.. *Acta Neurologica Belgica*, **2022**, 1.5